Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996449 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL812418 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2994601 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL953414 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL4628774 | 0.96 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2998727 | 0.96 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2991651 | 0.96 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2998728 | 0.96 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL943172 | 0.92 | MEN1 (0.39) | CHRNB2CHRNA7CHRNA4L3MBTL1PARP1 | |
| Proline SCHEMBL28261914 | 0.84 | GRIN2D (0.35) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | SEDELMEIER GOTTFRIED | 2010-07-22 | — | — | US | disclosed |
| US-20080200687-A1 | Preparation of Terazole Derivatives | SEDELMEIER GOTTFRIED | 2008-08-21 | — | — | US | disclosed |
| EP-1907378-A1 | PREPARATION OF TERAZOLE DERIVATIVES | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009716-A1 | PREPARATION OF TERAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200687-A1 | Preparation of Terazole Derivatives | TERB1, TALDO1, TERT | CHRNB2 3403/4885CHRNA7 1808/4885CHRNA4 2558/4885 |
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | TERB1, TALDO1, TERT | CHRNB2 3403/4885CHRNA7 1808/4885CHRNA4 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.